摘要
目的 探究康莱特联合唑来膦酸与多西他赛治疗转移性激素敏感性前列腺癌(mHSPC)的疗效。方法 回顾性分析2019年3月至2021年3月解放军第九六○医院收治的133例mHSPC患者的临床资料,依据其使用的不同治疗方案分为A组和B组。B组(n=59)使用唑来膦酸与多西他赛治疗,A组(n=74)在B组基础上加用康莱特治疗。对比两组临床疗效,使用视觉模拟评分法(VAS)、前列腺癌特异性补充量表(EORTC QLQ-PR25)分别评价患者治疗前后疼痛、生命质量情况,对比两组治疗前后血清碱性磷酸酶(ALP)、前列腺特异性抗原(PSA)水平及不良反应发生情况。结果 (1)A组临床总有效率为97.30%(72/74),显著高于B组的84.75%(50/59)(P=0.009);(2)治疗后,两组VAS评分均下降且A组[(5.01±1.89)分]明显低于B组[(6.97±1.65)分](P<0.001),EORTC QLQ-PR25评分均上升且A组[(62.39±8.61)分]明显高于B组[(36.67±9.55)分](P<0.001);(3)治疗后,两组ALP、PSA水平均显著降低且A组[(88.05±8.32)U/L、(43.02±4.39)mg/L]显著低于B组[(156.69±9.70)U/L、(59.43±4.41)mg/L](P<0.001);(4)A组不良反应总发生率为10.81%(8/74),明显低于B组的30.51%(18/59)(P=0.004)。结论 康莱特联合唑来膦酸与多西他赛治疗mHSPC疗效显著,能够有效降低患者疼痛程度及疾病相关指标水平,改善其生命质量,减少不良反应的发生情况。
Objective To investigate the efficacy of conwright combined with zoledronic acid and docetaxel in the treatment of metastatic hormone-sensitive prostate cancer(mHSPC).Methods Clinical data of 133 mHSPC patients admitted to the 960 th Hospital of PLA from March 2019 to March 2021 were retrospectively analyzed,and they were divided into group A and group B according to different treatment regimen.59 patients in group B were treated with zoledronic acid and docetaxel,74 patients in group A were treated with conwright on group B basis,and the clinical efficacy of the two groups were compared.Visual analogue scale(VAS) and prostate cancer specific supplement scale(EORTC QLQ-PR25) were used to evaluate the pain and quality of life of patients before and after treatment.The serum alkaline phosphatase(ALP),prostate specific antigen(PSA) levels and the incidence of adverse reactions in two groups were compared before and after treatment.Results (1) The total clinical response rate in group A was 97.30%(72/74),significantly higher than that in group B[84.75%(50/59)](P=0.009);(2) After treatment,VAS score in group A(5.01±1.89) was significantly lower than that in group B(6.97±1.65)(P<0.001),EORTC QLQ-PR25 score in group A(62.39±8.61) was significantly higher than that in group B(36.67±9.55)(P<0.001).(3) After treatment,the levels of ALP and PSA in group A [(88.05±8.32)U/L,(43.02±4.39)mg/L]were significantly lower than those in group B[(156.69±9.70)U/L,(59.43±4.41)mg/L](P<0.001).(4) The total incidence of adverse reactions in group A was 10.81%(8/74),which was significantly lower than that in group B [30.51%(18/59)](P=0.004).Conclusions Conwright combined with zoledronic acid and docetaxel has significant efficacy in the treatment of mHSPC,which can effectively reduce the pain degree and disease-related indicators of patients,improve their quality of life,and reduce the occurrence of adverse reactions.
作者
杨高第
陈晓杰
付宝琛
YANG Gaodi;CHEN Xiaojie;FU Baochen(Department of Urology,960th Hospital of PLA,Jinan 250031,Shandong,China;Department of Urology,Qianfoshan Hospital,Shandong Province,Jinan 250014,Shandong,China)
出处
《中国性科学》
2022年第9期24-28,共5页
Chinese Journal of Human Sexuality
